Activating the innate and adaptive immune system to recognize and attack tumors
A large number of cancers will respond to PD-1/PD-L1 checkpoint inhibitors; however, for patients with tumors that do not already express PD-L1, response to approved agents is often limited or minimal. PORT-2 and PORT-3 may be able to activate the immune response in these patients to effectively identify and target the tumor.
Portage Biotech’s invariant natural killer T-cell (iNKT) agonists, PORT-2 and PORT-3, lead to a broad reprogramming of the innate and adaptive immune system, enabling the body to recognize and attack tumors that contain few immune cells and usually go undetected. Both may be used alone or in combination with checkpoint inhibitors, potentially helping more patients respond to treatment.